STOCK TITAN

Immuron Limited - IMRN STOCK NEWS

Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.

Immuron Limited (NASDAQ: IMRN) is a pioneering Australian biopharmaceutical company that specializes in oral immunotherapy. The company focuses on developing and commercializing therapies utilizing polyclonal antibody products that target the human gut immune system and microbiome. Immuron's cutting-edge technology platform is designed to create orally stable therapeutics, offering potential 'oral targeted therapy' for a variety of immune-mediated and inflammatory disorders, including non-alcoholic steatohepatitis (NASH), diabetes, colitis, arthritis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis, and other chronic conditions influenced by the immune system.

These disorders represent growing areas of unmet medical need, where oral targeted therapy drugs could provide significant benefits due to their high safety profiles and minimal absorption. Immuron has successfully brought one product to market, serving as proof of concept for its oral immune technology platform. Additionally, the company boasts a robust pipeline of products in various stages of clinical development.

One of Immuron's prominent products is IMM-124E, a proprietary immunomodulatory agent aimed at treating gastrointestinal immune-mediated diseases, including fatty liver diseases. The company operates in two primary segments: Research and Development, and Hyperimmune Products.

Recent developments highlight Immuron's progress in the market. The company has reported increased sales of its travel-related product, Travelan®, especially in markets such as the USA and Canada. Notably, sales in the USA have exceeded expectations following the product’s launch on Amazon. The company is also exploring non-dilutive funding opportunities for its Phase 3 clinical trials and has filed a provisional patent application with the U.S. Patent Office to protect its innovative findings.

Immuron's strategy involves continuing to harness its unique oral immunotherapy platform to address significant medical needs, focusing on partnerships and collaborations to enhance its product offerings and market reach.

Rhea-AI Summary

Immuron (ASX: IMC; NASDAQ: IMRN) has reported record global sales for its over-the-counter immune supplement Travelan® in FY 2024. Global sales reached AUD$4.9 million, up 174% from the previous year. Australia led with AUD$3.7 million in sales, a 223% increase, while the USA achieved record sales of AUD$1.1 million, up 74%. The June 2024 quarter saw significant growth, with global sales up 253% year-over-year to AUD$1.3 million.

The company attributes this success to increased brand awareness investments and plans further growth in North America through increased brand investment and distribution. The sales surge aligns with rising international travel, as reported by the Australian Bureau of Statistics and the U.S. International Trade Administration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.36%
Tags
none
-
Rhea-AI Summary

Immuron (ASX: IMC; NASDAQ: IMRN) has filed a pre-IND application with the FDA for IMM-529, aimed at treating recurrent Clostridioides difficile infections (CDI). CDI affects over 400,000 people annually in the U.S., causing over 30,000 deaths. IMM-529 is being developed as an adjunct therapy to standard antibiotics, targeting Toxin B, spores, and vegetative cells of C. diff. Pre-clinical studies have shown promising results, including 80% prevention of primary disease and 67% protection against recurrence. The projected base case yearly revenue for IMM-529 is US$93 million, with potential expansion to US$141 million if used for first recurrence patients. The drug's oral dosing is considered advantageous over current complex treatments. Immuron is working with Monash University to produce antibodies from bovine colostrum. The PR highlights the urgent need for new CDI treatments due to rising antibiotic resistance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.36%
Tags
-
Rhea-AI Summary

Immuron's CEO, Steven Lydeamore, will present at the Emerging Growth Conference on June 13, 2024. Immuron, an Australian biopharmaceutical company traded on ASX (IMC) and NASDAQ (IMRN), invites individual and institutional investors, as well as advisors and analysts, to join the interactive presentation. The session starts at 2:00 PM US Eastern Standard Time and will last for 12 minutes. Participants are encouraged to submit questions in advance or during the event. If unable to attend live, an archived webcast will be available on EmergingGrowth.com and its YouTube channel.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
conferences
News
Rhea-AI Summary

Immuron (IMRN), an Australian biopharmaceutical company, announced significant board changes on May 31, 2024. Dr. Roger Aston resigned as Non-Executive Director after serving since 2012, including as Chairman until 2023. Over his tenure, Immuron advanced its commercial and clinical programs, especially in diarrhoea prevention and gut health, strengthened by its partnership with the US Military. Dr. Aston's leadership was pivotal during capital raisings and the COVID-19 pandemic. Effective June 1, 2024, Dr. Jeannie Joughin, with extensive experience in immunology and senior roles at major pharmaceutical companies, will join as a Non-Executive Director, expected to enhance Immuron's strategic and commercial direction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
-
Rhea-AI Summary

Immuron CEO Steven Lydeamore will be presenting at Peak Asset Management's Peak Sky High luncheon in Melbourne on June 1, 2024.

Immuron , an Australian-based biopharmaceutical company, is listed on the ASX as IMC and NASDAQ as IMRN.

The presentation slide deck is available on the company's website.

This press release was authorized by the directors of Immuron.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
conferences
-
Rhea-AI Summary

Immuron , an Australian biopharmaceutical company, will be presenting at the Emerging Growth Conference on May 8, 2024. Investors, analysts, and advisors can interact with the CEO, Steven Lydeamore, during the live event. Questions can be submitted in advance or during the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
conferences
News
Rhea-AI Summary

Immuron announces the resignation of Non-Executive Director Stephen Anastasiou to focus on other business interests. Stephen has been with the company since 2013, contributing to the launch of Travelan® in the USA and Canadian markets and dual listing on NASDAQ (IMRN). His departure is aimed at restructuring his business commitments to spend more time with family and pursue personal interests. Immuron Chairman expresses gratitude for Stephen's marketing and clinical contributions and wishes him success in future endeavors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
management
-
News
Rhea-AI Summary
Immuron (ASX: IMC; NASDAQ: IMRN) announces a Live Virtual Event featuring positive Phase 2 Travelan results and upcoming Phase 3 clinical trials. The event will showcase the company's success in developing oral immunotherapeutics for gut-mediated diseases, with significant reductions in diarrhea cases and promising revenue projections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
conferences
-
Rhea-AI Summary
Immuron (IMRN) reports significant sales growth for Travelan®, an immune supplement, in Australia and the USA. FYTD Mar 2024 sales reached AUD$3.6 million, up 154% from the prior year, with Australia leading at AUD$2.8 million, up 234%. Sales on Walmart.com have commenced. The company aims to expand brand awareness and distribution in North America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
none
Rhea-AI Summary
Immuron Limited announces positive interim topline results for Travelan® in preventing moderate to severe diarrhea caused by ETEC. The Phase 2 study showed significant protective efficacy with a single daily dose, supported by funding from the U.S. Department of Defense. The study demonstrated a 36.4% protective efficacy against moderate to severe diarrhea and a 66.7% protective efficacy against severe diarrhea compared to the placebo group. Additionally, there was an 83.3% reduction in subjects needing early antibiotic treatment and a 100% reduction in subjects requiring IV fluids post challenge in the Travelan® group. The study also reported a 55.6% reduction in adverse events associated with the ETEC challenge in the Travelan® group. The Phase 2 study data supported the excellent safety and tolerability profile of Travelan®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
175.76%
Tags

FAQ

What does Immuron Limited do?

Immuron Limited specializes in developing oral immunotherapy treatments using polyclonal antibody products targeting the human gut immune system and microbiome.

What are some diseases Immuron targets with its therapies?

Immuron targets diseases such as non-alcoholic steatohepatitis (NASH), colitis, diabetes, arthritis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and liver fibrosis.

What is IMM-124E?

IMM-124E is Immuron's proprietary immunomodulatory agent aimed at treating gastrointestinal immune-mediated diseases, including fatty liver diseases.

How many segments does Immuron operate in?

Immuron operates in two segments: Research and Development, and Hyperimmune Products.

What recent achievements has Immuron reported?

Immuron has reported increased sales of Travelan® in the USA and Canada. The company also launched the product on Amazon in the USA, with sales exceeding expectations.

What are Immuron's future plans?

Immuron plans to continue developing its oral immunotherapy platform, explore non-dilutive funding for Phase 3 clinical trials, and expand its patent portfolio.

How is Immuron expanding its market presence?

Immuron is expanding its market presence through product launches on platforms like Amazon, increasing sales, and exploring new funding opportunities for clinical trials.

What makes Immuron's therapies unique?

Immuron's therapies are unique due to their focus on orally stable polyclonal antibodies that target the gut immune system, providing high safety profiles and minimal absorption.

Has Immuron filed any patents recently?

Yes, Immuron has filed a provisional patent application with the U.S. Patent Office to protect its recent innovative findings.

What is Travelan®?

Travelan® is one of Immuron's marketed products designed to prevent travelers’ diarrhea, and it has seen increased sales in recent months.

Immuron Limited

Nasdaq:IMRN

IMRN Rankings

IMRN Stock Data

15.05M
228.00M
0.69%
0.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Melbourne